| Literature DB >> 35384164 |
Nicole Pizzorni1, Andrea Ciammola2, Giovanni Casazza3, Daniela Ginocchio4, Federica Bianchi4, Sarah Feroldi4,5, Barbara Poletti2, Lorenzo Nanetti6, Caterina Mariotti6, Gabriele Mora4, Antonio Schindler1.
Abstract
BACKGROUND ANDEntities:
Keywords: deglutition disorders; malnutrition; neurodegenerative diseases
Mesh:
Year: 2022 PMID: 35384164 PMCID: PMC9540307 DOI: 10.1111/ene.15345
Source DB: PubMed Journal: Eur J Neurol ISSN: 1351-5101 Impact factor: 6.288
Demographic and clinical characteristics of study participants
| Variable |
Overall,
|
HD,
|
PD,
|
ALS,
|
|
|---|---|---|---|---|---|
| Demographic characteristics | |||||
| Age, years | 67 [56–75] | 58.5 [48–67.8] | 75.5 [64–79.5] | 69 [61.3–75] | <0.001 |
| Gender | |||||
| Male | 79 (53.4%) | 22 (40.7%) | 25 (75.8%) | 32 (52.5%) | 0.011 |
| Female | 69 (46.6%) | 32 (59.3%) | 8 (24.2%) | 29 (47.5%) | |
| Clinical characteristics | |||||
| Disease duration, years | 5 [1.3–9] | 7 [4–10] | 9 [4–12] | 2 [1–5] | <0.001 |
| History of aspiration pneumonia | 5 (3.4%) | 2 (3.7%) | 2 (6.1%) | 1 (1.6%) | 0.519 |
| Oral nutritional supplements | 30 (19.1%) | 15 (27.7%) | 1 (3%) | 14 (23%) | 0.016 |
| Disease severity | |||||
| Mild | 59 (39.9%) | 22 (40.7%) | 15 (45.5%) | 22 (36.1%) | 0.465 |
| Moderate | 53 (35.8%) | 17 (31.5%) | 9 (27.3%) | 27 (44.3%) | |
| Severe | 36 (24.3%) | 15 (27.8%) | 9 (27.3%) | 12 (19.7%) | |
| Diet type | |||||
| No restriction | 48 (32.4%) | 23 (42.6%) | 8 (24.2%) | 17 (27.8%) | 0.216 |
| Modified diet | 100 (67.6%) | 31 (57.4%) | 25 (75.8%) | 44 (72.2%) | |
Values are presented as n (%) or as median [interquartile range]. Demographic and clinical variables were compared among the three diagnoses using the chi‐squared test for categorical variables and the Kruskal–Wallis test with post hoc test and Bonferroni correction for continuous variables. Disease severity was categorized based on disease‐specific rating scales as follows: HD, Unified Huntington's Disease Rating Scale Part IV score 13–7 = mild, 6–4 = moderate, 3–0 = severe; PD, Hoehn & Yahr stage 1–2.5 = mild, 3 = moderate, 4–5 = severe; ALS, ALS Functional Rating Scale–Revised score = 48–34 mild, 33–17 = moderate, 16–0 = severe.
Abbreviations: ALS, amyotrophic lateral sclerosis; HD, Huntington disease; PD, Parkinson disease.
Statistically significant p‐values.
HD vs PD p < 0.05 at post hoc analysis.
HD vs ALS p < 0.05 at post hoc analysis.
PD vs ALS p < 0.05 at post hoc analysis.
Demographic, clinical, and swallowing factors associated with malnutrition risk based on univariate and multivariate logistic regression analysis
| Factors | Univariate analysis, | Multivariate analysis, initial model, | Multivariate analysis, final model, | |||
|---|---|---|---|---|---|---|
| OR (CI 95%) |
| OR (CI 95%) |
| OR (CI 95%) |
| |
| Demographic and clinical factors | ||||||
| Age, <65 vs ≥65 years | 2.60 (1.28–5.27) | 0.008 | 2.80 (1.07–7.34) | 0.036 | 3.16 (1.26–7.89) | 0.014 |
| Gender, F vs M | 1.53 (0.76–3.07) | 0.236 | – | – | ||
| Diagnosis | 0.185 | – | – | |||
| HD vs ALS | 0.47 (0.21–1.05) | |||||
| PD vs ALS | 0.65 (0.26–1.65) | |||||
| Disease severity | 0.001 | 0.008 | 0.003 | |||
| Moderate vs mild | 2.24 (1.03–4.86) | 3.68 (1.34–10.06) | 3.89 (1.47–10.29) | |||
| Severe vs mild | 10.63 (2.94–38.53) | 10.85 (1.64–71.61) | 9.71 (1.83–51.56) | |||
| Diet type, modified diet vs no restriction | 4.56 (2.17–9.56) | <0.001 | 1.05 (0.39–2.86) | 0.918 | – | |
| FEES findings, present vs absent | ||||||
| Valleculae residue, present vs absent | 2.08 (0.99–4.34) | 0.053 | – | – | ||
| Pyriform sinus residue, present vs absent | 1.93 (0.96–3.88) | 0.064 | – | – | ||
| Penetration, present vs absent | 2.32 (1.10–4.90) | 0.027 | 1.56 (0.53–4.61) | 0.418 | – | |
| Aspiration, present vs absent | 1.77 (0.76–4.12) | 0.185 | – | – | ||
| Oral phase efficiency, continuous | ||||||
| TOMASS bites | 1.26 (0.99–1.60) | 0.052 | – | – | ||
| TOMASS masticatory cycles | 1.03 (1.01–1.06) | 0.011 | 1.04 (1.00–1.07) | 0.082 | 1.03 (1.01–1.06) | 0.044 |
| TOMASS swallows | 1.25 (0.94–1.67) | 0.131 | – | – | ||
| TOMASS time | 1.02 (1.01–1.04) | 0.012 | 1.00 (0.98–1.02) | 0.777 | – | |
| Meal observation, continuous | ||||||
| MAS safety | 1.41 (1.11–1.79) | 0.004 | 1.42 (1.04–1.93) | 0.028 | 1.44 (1.07–1.94) | 0.016 |
| MAS efficacy | 1.11 (0.94–1.32) | 0.205 | – | – | ||
| Meal duration | 0.99 (0.95–1.03) | 0.731 | – | – | ||
For categorical variables, OR > 1 means a higher probability of the reference group than the control group to be at risk of malnutrition. For continuous variables, OR > 1 means that an increase of 1 point in the value of the variable increases the probability of malnutrition risk.
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; F, female; FEES, fiberoptic endoscopic evaluation of swallowing; HD, Huntington disease; M, male; MAS, Mealtime Assessment Scale; OR, odds ratio; PD, Parkinson disease; TOMASS, Test of Masticating and Swallowing Solids.
Final model after using backward elimination method of variable selection.
Significant p‐values.